Two leading biotech companies have developed the first fully synthetic, cell-free manufacturing platform for personalized RNA-based cancer therapeutics, marking a major leap in medical innovation by halving production time and significantly improving safety.
According to Iran’s Special Headquarters for Nanotechnology Development, Ilgen (a next-generation DNA producer) and Nutcracker Therapeutics (an expert in RNA design and manufacturing) have launched a pilot program integrating their advanced technologies to transform access to personalized cancer treatments.
The platform features three core components:
By eliminating bacterial cells from the DNA production process, the system avoids microbial and endotoxin contamination risks and achieves unmatched precision and speed in DNA synthesis.
Matthew Hill, CEO of Ilgen, stated, “Removing cells from the production process accelerates the development of new therapies, giving patients faster access to treatment.”
Benjamin Eldridge, CTO of Nutcracker Therapeutics, added, “We are not only improving manufacturing processes but also laying the groundwork for democratizing personalized medicine.”
This technological breakthrough is expected to:
If the pilot proves successful, the pharmaceutical industry could experience rapid expansion in personalized therapy development and broader access to advanced treatments worldwide ushering in a new era of precision medicine in cancer care.